MedTrace Logo

A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

NCT02149706 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2020-03-11

No results posted yet for this study

Summary

Multi-center, randomized , double-blind, placebo-controlled , two arm parallel design study of NeuroVax™ vs. Incomplete Freund's Adjuvant ( I F A) placebo. 150 subjects with Secondary Progressive SPMS.

Conditions

Interventions

BIOLOGICAL

NeuroVax

NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA

BIOLOGICAL

IFA Incomplete Freund's Adjuvant

IFA Placebo Incomplete Freund's Adjuvant

Sponsors & Collaborators

  • cro

    collaborator AMBIG

  • Immune Response BioPharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Richard M Bartholomew, Ph.D · Immune Response BioPharma, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-09
Primary Completion
2022-03-09
Completion
2022-03-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02149706 on ClinicalTrials.gov